课题基金 / 基金详情

Roles of transbronchial factors including cigarette smoke and asbestos for rapidly increasing lungcancer

Roles of transbronchial factors including cigarette smoke and asbestos for rapidly increasing lungcancer
香烟烟雾和石棉等经支气管因素对肺癌迅速增加的作用
批准号:
11470052
负责人:
ISHIKAWA Yuichi
金额:
$4.16万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001

项目摘要

项目成果

ISHIKAWA Yuichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To investigate the causes of rapidly increasing lung cancer in Japan, we analysed both genetic changes and carcinogenic inhalants including smoking and asbestos. We examined primary lung cancers (9 in 1950s, 52 in 1970s and 60 1990s) in terms of asbestos deposition in the lung. Mean asbestos body concentrations (numbers per g of lung (dry)) were 559, 1804 and 563 in 1950s, 1970s and 1990 s, respectively. Statistically significant elevation in the concentration of 1970s was noted as compared to that of 1990s (p<0.005). Since the lung cancer incidence in Japan has been rising from 1950 to 1990, asbestos exposure is not thought to be a main cause of lung cancer increase. Further, we compared asbestos concentrations in the lung between primary and metastatic lung adenocarcinomas in 1970s. Also, we examined differentiation grades, LOH frequency (presented by FAL values) and p53 mutations in lung adenocarcinomas in 1990s, subclassified to 3 groups by asbestos body concentration (AB, numbers/dry g) : zero AB group (AB=0, n=21), low AB group (0<AB<1000, n=14 and high AB group (1000=<AB, n=l1). AB in primary cancers in 1970s was 2050 in males, significantly higher than that of metastatic cancers, 703, although the difference was not significant in females. In the three groups, well/moderate./poor. were 6/11/4, 6/8/0, 4/7/0 ; FAL values were 0.17, 0.07, 0.13 ; and p53 mutation frequencies were 3/19, 4/14, 5/11. Regardless of asbestos levels, well and moderatelydifferentiated carcinomas were predominant and FAL values were smaller than that for smokers (0.21, n=66). Interestingly, p53 mutation frequency was significantly more frequent in high AB group than in zero AB group (p =0.006).
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Hayashi M, Ishikawa Y et al.: "Reduced HIC-1 expression in non-small cell lung cancer and its clinical significance"Anticancer Res. 21. 535-540 (2001)
Hayashi M、Ishikawa Y 等:“非小细胞肺癌中 HIC-1 表达降低及其临床意义”Anticancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishikawa Y. et al.: "Problems in histological diagnosis of cancer associated with chemo-and/or radiotherapy"J Cancer Res Clin Oncol. 125. 239-244 (1999)
Ishikawa Y.等人:“与化疗和/或放疗相关的癌症的组织学诊断问题”J Cancer Res Clin Oncol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hayashi M, Ishikawa Y et al.: "Reduced HIC-1 expression in non-small cell lung cancer and its clinical significance."Anticancer Res. 21. 535-540 (2001)
Hayashi M、Ishikawa Y 等人:“非小细胞肺癌中 HIC-1 表达降低及其临床意义。”Anticancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tokuchi Y.,Ishikawa Y.et al.: "Abnormal FHIT transcripts found in both lung cancer"Genes Chromosomes Cancer. 24. 105-111 (1999)
Tokuchi Y.、Ishikawa Y.等人:“在两种肺癌中发现异常的 FHIT 转录本”基因染色体癌。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
11
    Regulation of cytoplasmic HDACs relating HSP90 protein
    • 批准号:
      25860965
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.25万
    • 财政年份:
      2013
    • 负责人:
      ISHIKAWA Yuichi
    • 依托单位:
    A study based on geographical research of TOD in middle-sized cities in local areas
    • 批准号:
      23520963
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.0万
    • 财政年份:
      2011
    • 负责人:
      ISHIKAWA Yuichi
    • 依托单位:
    Creating a New Functional Fluid stemming from the Mixture of"Ionic Liquid - Magnetic particle - Nano Carbon"
    • 批准号:
      23655181
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.58万
    • 财政年份:
      2011
    • 负责人:
      ISHIKAWA Yuichi
    • 依托单位:
    Synthesis of novel inhibitors of hypoxia-inducible factor-1 transcriptional pathway based on natural products
    国内基金
    海外基金
    靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡文静
    • 依托单位:
    HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
    • 批准号:
      81960115
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      34.0万元
    • 批准年份:
      2019
    • 负责人:
      江建宁
    • 依托单位:
    基于自适应表面肌电模型的下肢康复机器人“Human-in-Loop”控制研究
    • 批准号:
      61005070
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2010
    • 负责人:
      李庆玲
    • 依托单位: